Our director Brian Rudd is speaking at the Society of Experimental Biology Meeting in Manchester on Tuesday 1 July. The title of his talk is “Synthetic Biology for renewable fuels and chemicals ; an industrial perspective”.
Come and meet our team at SynBioBeta on 2-3 April 2014. Our CEO Steve Martin will talk about our exciting work in engineering microbes to produce high value chemicals.
Dr Steven Martin has been appointed to the position of CEO and Director of Biosyntha as of 15th July 2013, taking over from interim manager Ann Kramer. Since foundation in Jan 2012 Biosyntha has doubled both its contract research services business and its proprietary research team. The company is now expanding its laboratory facilities and strengthening its commercial position in the industrial biotechnology sector.
Steve Martin has a background in technical and commercial development of bioprocesses in the Pharmaceutical and Industrial Biotechnology sectors. He has a successful track record of building and directing cross-disciplinary teams to develop innovative products and processes and transition them quickly to market. Steve is recognised for his ability to communicate effectively to a wide audience including the public and private sectors.
In 2012, Steve founded Inspire Biotech Ltd a consultancy company set up to catalyse the growth of Industrial Biotechnology in the UK.
Steve was formerly Executive R&D Director at TMO Renewables Ltd, where he was responsible for the internal and external research programs focussed on developing their proprietary thermophilic bacterium (Geobacillus spp.) into a robust industrial platform for the production of biofuels and chemicals from waste biomass. During his tenure at TMO, Steve set up the research labs in Guildford, recruited a talented research team and helped the Company raise more than £50m in financing to transition their technology from concept to commercialisation. In addition, he was responsible for business development in China including collaborations with a number of large state-owned companies and Universities.
Prior to TMO, Steve was Head of Fermentation at Cubist Pharmaceuticals and was responsible for the UK pilot plant and the fermentation activities at two manufacturing sites in Italy. He was lead scientist on the fermentation process development and scale-up of the first-in-class lipopeptide antibiotic daptomycin (Cubicin™). Prior to this he held research management positions at TerraGen Discovery, Inc. and Xenova Discovery Ltd. He has more than 20 years industrial experience in microbial fermentation and has authored many peer-reviewed scientific papers, articles and book chapters. He received both his degree and his PhD from the University of Surrey.
Brian Rudd will be presenting a paper with Professor David Fell on the application of metabolic modeling to acetogenic bacteria at the ACCLIPHOT Metabolic Pathway Analysis 2013 conference at Corpus Christi College in Oxford from 16th – 20th September. For more information click here
Eight synthetic biology (synbio) companies have joined the BioIndustry Association (BIA) to form a new group working on this emerging area of bioscience.
Synbio is the design and engineering of biologically based parts, novel devices and systems as well as the redesign of existing, natural biological systems. It has the potential to deliver important new applications and improve existing industrial processes – resulting in economic growth and job creation.
The eight companies founding the BIA synbio group are: Algenuity, Biosyntha, Genabler, Green Biologics, Oxitec, Prokarium, Synpromics and Synthace.
Lionel Clarke, Chairman of the UK Synbio Leadership Council said:
“I am extremely pleased to see that the Roadmap is already delivering such a positive impact – raising the profile of Synthetic Biology companies within the UK, and galvanising action aligned with our vision. This will provide a valuable forum for bringing together and representing the ongoing interests of this rapidly developing industrial community.”
For the full press release click here
BioSyntha is delighted to announce the appointment of Dr Mike Goosey as non-executive director with immediate effect.
Mike is a bioenergy and industrial biotechnology consultant and is an honorary Professor in Sustainable Bioenergy at the University of Nottingham. He is a member of Council for the BBSRC. Mike was previously with the Royal Dutch Shell Company for 21 years. He served as Global Manager for Shell’s R&D Biofuels Programme in Shell’s Alternative Energies business. In this role he led multi-disciplinary R&D teams in the Americas, Europe and SE Asia, both within Shell, Universities, Institutes and in partnerships with biotechnology start-ups such as Iogen, Codexis, Cellana and Virent.
In his previous assignments he was the Global Manager for Pervasive R&D Technologies, supporting Shell’s Refinery operations, LNG and Chemicals businesses. His team also provided trackside support for the Ferrari F1 team. Previous to this, he was responsible for the biochemical and molecular biology team at Sittingbourne Research Centre, UK involved in the molecular design of Agrochemicals.
Mike has a PhD in Biochemistry and was a Parkinson’s Disease Research Fellow at the Medical School, Birmingham University, UK, before joining Dow Chemical Company where he worked for 6 years in the Agrochemical Business. Mike was made a Fellow of the Royal Society of Chemistry in 2007.
BioSyntha Technology Ltd. is an industrial biotechnology company that offers bespoke contract research services to diverse industries as well as developing proprietary systems for the fermentation of high value chemicals from renewable raw materials. Industrial biotechnology has been identified by BBSRC as a strategic priority area for UK R&D, helping the country to become a lower carbon economy.
BioSyntha was created by spinning out the experienced industrial biotechnology team, together with relevant assets, from Novacta Biosystems. BioSyntha is focusing its resources on opportunities in industrial biotechnology, while Novacta continues to develop its therapeutic programmes. The new company operates out of well-equipped former Novacta facilities at the BioPark in Hertfordshire.
BioSyntha’s scientific team has decades of experience and expertise in metabolic pathway engineering and fermentation, biocatalysis process development, production of API and agrochemical metabolites and natural product development. Other capabilities include enzyme development and production, protein production, analytical method development and classical development of microbes.
BioSyntha makes these capabilities available to clients on a fee-for-service or collaborative basis.
For more information contact firstname.lastname@example.org